In atrial fibrillation, the biomarker‐based ABC‐stroke score, combining age, NT‐proBNP, high‐sensitivity cardiac troponin, and clinical history of prior stroke or transient ischemic attack, demonstrated better discrimination than CHA2DS2‐VASc in both the derivation cohort (C‐index 0.68 vs. 0.62) and the external validation cohort (0.66 vs. 0.58) [115]. This evidence concerns the gene NPPB and Stroke.